Not Signed In -
Kava-Kava |
Awa; Kava; Kawa; Kew; Piper methysticum; Yagona |
Clinical Trial: Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)
This study has been terminated.
|
Purpose
The purpose of this study is to evaluate the safety and effectiveness of the herbal medicine kava kava for the treatment of generalized anxiety disorder (GAD).
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Anxiety Disorders | Drug: Kava kava Drug: Venlafaxine-XR | Phase II |
MedlinePlus related topics: Anxiety
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: KAVA KAVA in Generalized Anxiety: A Double-Blind Trial
Expected Total Enrollment: 124
Kava kava (KAV) is a plant-derived treatment widely used in Europe to treat anxiety disorders. Several studies suggest that KAV may be effective in reducing anxiety symptoms; however, trial data are limited. This study will compare KAV, the drug venlafaxine-XR (VEN), and placebo for the treatment of GAD.
This study will last 10 weeks. Participants will be randomly assigned to receive KAV, VEN, or placebo for 8 weeks. Participants will then undergo a 1-week tapering of their medication followed by an additional week of observation. Self-report scales and questionnaires will be used to assess the anxiety, depression, and functional impairment of participants. Side effects, vital signs, and laboratory measures will be monitored throughout the study.
Eligibility
Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Diagnosis of generalized anxiety disorder (GAD)
Location Information
Jonathan Davidson, MD, Principal Investigator, Duke University
More Information
Record last reviewed: November 2004
Last Updated: November 12, 2004
Record first received: June 4, 2004
ClinicalTrials.gov Identifier: NCT00083980
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
